Results 141 to 150 of about 223,686 (290)

Epilepsy Phenotypic Spectrum of NUS1‐Related Disorder: A Case Series

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Background Epilepsy with myoclonic and atonic seizures (EMAtS), also known as Doose syndrome, accounts for 1%–2% of childhood epilepsies, and various genes have been implicated in causing this epilepsy syndrome. NUS1 encodes for Nogo‐B receptor (NgBR), which stabilizes the dehydrodolichyl‐diphosphate synthase complex in the endoplasmic ...
Saumel Ahmadi   +6 more
wiley   +1 more source

Sustainable curriculum innovation through educational design research in conservatoire education

open access: yesThe Curriculum Journal, EarlyView.
Abstract This study reported a four‐year educational design research (EDR) project at a Dutch conservatoire, where researchers and practitioners collaboratively redesigned the Bachelor of Music curriculum. Through iterative, practitioner‐led cycles of exploration, prototyping, implementation, and evaluation, the intervention produced a shared ...
Tamara Rumiantsev   +2 more
wiley   +1 more source

Neurofeedback for Binge‐Eating Disorder: Neurophysiological Outcome Predictors and Rapid Response

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Pioneer studies suggested the effectiveness of food‐specific electroencephalography (EEG) and real‐time functional near‐infrared spectroscopy (rtfNIRS) neurofeedback (NF) trainings in the treatment of binge‐eating disorder (BED). These trainings aim to improve participants' neurophysiological self‐regulation.
Ben Schreglmann   +3 more
wiley   +1 more source

Multivariate Trajectories of Eating Disorder Symptoms and Weight Status in 10‐ to 17‐Year‐Old Children and Adolescents

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Eating disorders (EDs) often emerge in adolescence, but developmental trajectories across different core features remain largely unclear. Method The prospective, community‐based study included N = 898 participants aged 9.5–17.5 years (47.6% female, age 11.8 ± 1.4 years) with annual follow‐up over 2–6 (3.4 ± 1.2) years.
Anja Hilbert   +5 more
wiley   +1 more source

The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 733-760, April 2025.
Abstract Implantable cardioverter defibrillators (ICDs) reliably prevent death due to life‐threatening arrhythmias; this may become less relevant in people with more severe heart failure who are reaching the end of life (EOL). This review aimed to explore the ICD deactivation process and identify ethical issues, especially around the initiation of ...
Siobhan C. Murray   +2 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya   +9 more
wiley   +1 more source

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki   +11 more
wiley   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul   +13 more
wiley   +1 more source

Speech Rhythm Convergence as a Social Coalition Signal. [PDF]

open access: yesEvol Psychol, 2019
Polyanskaya L, Samuel AG, Ordin M.
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy